Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $5.8333.

A number of equities research analysts have commented on SRTS shares. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Lake Street Capital cut their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $3.34 on Monday. The company has a market capitalization of $54.98 million, a price-to-earnings ratio of -3.55 and a beta of 1.10. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49. The company’s fifty day moving average price is $2.99 and its 200-day moving average price is $3.57.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. EP Wealth Advisors LLC bought a new stake in Sensus Healthcare in the 2nd quarter valued at $49,000. BlackRock Inc. purchased a new stake in Sensus Healthcare in the 2nd quarter worth $252,000. Bank of New York Mellon Corp bought a new position in shares of Sensus Healthcare during the 2nd quarter valued at about $303,000. North Star Investment Management Corp. bought a new position in shares of Sensus Healthcare during the 1st quarter valued at about $500,000. Finally, XTX Topco Ltd purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at about $77,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.